Jonathan Ostrem, MD, PhD

Assistant Adjunct Professor

Our laboratory uses chemical biology approaches to develop new modes of cancer therapy. We are interested in the design of small molecule and antibody-based cancer therapeutics directed at oncogenic signaling pathways. To accomplish this we use a variety of techniques, including synthetic organic chemistry, biochemistry, protein engineering, and cellular and mouse models of human cancer.

Education
06/2022 - Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
06/2018 - Internal Medicine, Brigham and Women's Hospital, Harvard Medical School
MD, 06/2016 - , University of California, San Francisco
PhD, 09/2013 - Chemical Biology, University of California, San Francisco
Honors and Awards
  • Forbes 30 Under 30: Science & Healthcare, Forbes Magazine, 2014
  • Joseph E. Mayer Award, University of California, San Diego, 2007
  • Phi Beta Kappa, University of California, San Diego, 2007
  • Thomas E. Curtis Scholarship, University of California, San Diego, 2006
Websites
Publications

  1. Ostrem JML, Peters U, Shokat KM. Direct RAS inhibitors turn 10. Nature chemical biology 2024. PMID: 39060392


  2. Li W, Garcia-Rivera EM, Mitchell DC, Chick JM, Maetani M, Knapp JM, Matthews GM, Shirasaki R, de Matos Simoes R, Viswanathan V, Pulice JL, Rees MG, Roth JA, Gygi SP, Mitsiades CS, Kadoch C, Schreiber SL, Ostrem JML. Highly specific intracellular ubiquitination of a small molecule. bioRxiv : the preprint server for biology 2024. PMID: 38328167


  3. Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL. Rational Screening for Cooperativity in Small-Molecule Inducers of Protein-Protein Associations. Journal of the American Chemical Society 2023. PMID: 37816014


  4. Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL. Rational screening for cooperativity in small-molecule inducers of protein-protein associations. bioRxiv : the preprint server for biology 2023. PMID: 37292909


  5. Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC. Overcoming KRAS-Mutant Lung Cancer. Volume 42. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022. PMID: 35412860


  6. Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Volume 15 of Issue 11. Nature reviews. Drug discovery 2016. PMID: 27469033


  7. Schroeder CM, Ostrem JM, Hertz NT, Vale RD. A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region. Volume 3. eLife 2014. PMID: 25272277


  8. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, Chien HC, Zhang Y, Morrissey KM, Liu J, Ostrem J, Younger NS, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Volume 111 of Issue 27. Proceedings of the National Academy of Sciences of the United States of America 2014. PMID: 24961373


  9. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Volume 503 of Issue 7477. Nature 2013. PMID: 24256730